← brief for 2026-09-03 · Slowing decline

Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial.

Article B Peer reviewed Small trial

Key takeaways

This is a second look at data from a randomized trial comparing semaglutide and empagliflozin in people with type 2 diabetes. It asks whether either drug improves the health of the endothelium, the thin lining inside blood vessels that controls blood flow and inflammation. The idea being tested is whether better vessel lining explains why both drugs cut heart risk. The abstract available here does not give the number of people or the length of the trial, and the measures are blood vessel markers, not kidney outcomes.

Who did this work

Gullaksen S · Vernstrøm L · Sørensen SS · Funck KL · Poulsen PL · Laugesen E

Source

Article · PubMed, the drug frontier · 2026 Aug 29
https://pubmed.ncbi.nlm.nih.gov/42679726/